Kyverna Therapeutics

Edit info

Founded: 2018

Location: Berkeley, CA

Employee range: 50 - 200

Clinical stage: Clin0

Therapy area: Lupus nephritis (FT)

Drug types: IMM, NPH

Lead product: KYV-101

Funding: $60M B Aug 2023; $85M B Jan 2022; $25M A Jan 2020

Investors: Vida Ventures, Westlake Village Partners, Bain Capital Life Sciences, GordonMD Global Investments LP, Gilead Sciences, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital

kyvernatx.com

linkedin.com

job board

Drug notes:

KYV-201 RD autoimmune diseases

About:

Kyverna Therapeutics is engineering cell therapies for autoimmune and inflammatory diseases. Many autoimmune diseases lack optimal treatment for patients. Through the use of synthetic biology, immunology and cell engineering, Kyverna is using their SmarTcell platform to advance technologies to treat the cause of these diseases. Kyverna’s technologies include chimeric antigen receptor T cells designed to eliminate pathogenic cells in specific organs and tissues. Kyverna is also developing synthetic versions of Regulatory T cells to control immune homeostasis. Current therapies are in clinical trials for B-cell driven autoimmune diseases.